Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
glp-1 obesity drug news october 2025 Patients Face New Barriers for Drugs not-discarded Purchase Plan:3-Months Supply Eli Lilly's GLP-1 outdoes
Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial
Kind Patches’ marketing materials include several claims that could violate ASA guidelines: “92.3% of participants reported fewer cravings” (unsubstantiated efficacy claim) Before/after style testimonials without clinical backing Implications that patches work similarly to prescription medications Claims about “supporting GLP-1 production” without evidence The ASA considers testimonials making medical claims as advertising, regardless of whether they’re “genuine” customer experiences
not-discarded
Purchase Plan:3-Months Supply
Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell
US$ 20.57
US$ 25.53
US$ 27.57
